Kisspeptin-10 Shows Promise for Pulmonary Hypertension by Restoring Cell Energy
Background
Pulmonary arterial hypertension (PAH) is a severe and progressive lung condition characterized by high blood pressure in the arteries leading to the lungs, often leading to heart failure. A key driver of PAH is mitochondrial dysfunction and dysregulated mitophagy (the cellular process of clearing damaged mitochondria) in pulmonary artery smooth muscle cells (PASMCs). This study addresses how Kisspeptin-10 might mitigate PAH by targeting these critical cellular energy and quality control issues.
Study Design
Results
Treatment with Kisspeptin-10 significantly attenuated PAH in the mouse model. They observed a considerable reduction in the systolic pressure of the right ventricle, along with decreased right ventricular hypertrophy and pulmonary vascular remodeling. Mechanistically, Kisspeptin-10 restored mitochondrial membrane potential, ATP production, and cytochrome c oxidase activity in both hypoxic PASMCs and PAH lung tissues. >The peptide normalized the excessive accumulation of mitophagy proteins PINK1, Parkin, and FUNDC1, indicating a restoration of proper mitochondrial quality control and removal of damaged organelles. In vitro, Kisspeptin-10 directly inhibited hypoxia-induced PASMC proliferation, a key pathological process contributing to vascular remodeling in PAH.
Why It Matters
This research highlights the Kisspeptin/GPR54 axis as a novel and promising therapeutic target for PAH, a disease with limited effective treatments. By restoring mitochondrial function and normalizing mitophagy in PASMCs, Kisspeptin-10 offers a new approach to combat the underlying cellular pathology of this devastating disease. These findings provide strong preclinical evidence that could pave the way for future human trials and the development of new PAH treatments. Further research would involve optimizing dosing, evaluating long-term safety and efficacy in larger animal models, and eventually progressing to Phase I clinical trials.